sickle

Voxelotor (GBT 440) is a novel hemoglobin S (HbS) polymerization inhibitor primarily used for the treatment of sickle cell disease (SCD) and a cytochrome P450 3A4 inhibitor. Voxelotor targets and covalently binds to the N-terminal valine of the HbS alpha chain, thereby stabilizing sickle cell hemoglobin (HbS).

PF-04447943 (Edelinontrine) is a potent and selective phosphodiesterase 9A inhibitor with an IC50 of 12 nM, which is 78-fold more selective than that used for other PDE family members (IC50>1000 nM).PF-04447943 exhibits anti-inflammatory activity, attenuates inflammatory responses by inhibiting oxidative stress, inflammation, and modulating T-cell polarization, and may be useful for research on sickle cell anemia.

Velaresol (BW 12C79) is used for the study of tumors, sickle cell anemia and digestive disorders.

MS8511, a selective covalent irreversible inhibitor of G9a GLP, targets a cysteine residue at the substrate binding site, displaying IC50 values of 100 nM (G9a) and 140 nM (GLP), alongside Kd values of 44 nM (G9a) and 46 nM (GLP). This compound effectively reduces cellular H3K9me2 levels and boosts antiproliferation activity, making it applicable in cancer research involving brain, breast, ovarian, lung, bladder, melanoma, and colorectal cancers, as well as studies on Alzheimer's disease (AD), sickle cell disease, and Prader−Willi syndrome (PWS) [1].

(Rac)-Etavopivat ((Rac)-FT-4202), an isomer of Etavopivat, is an orally active erythrocyte pyruvate kinase-R (PKR) activator used in sickle cell disease and haemoglobinopathy research [1].

D-fructose-1,6-diphosphate (D-fructose-1,6-diphosphate), also known as Fosfructose, is a cytoprotective natural sugar phosphate. It functions by promoting anaerobic glycolysis, which generates adenosine triphosphate (ATP) under ischemic conditions. This compound holds potential for research in cardiovascular ischemia, sickle cell anemia, and asthma.

Esafosfan trisodium (FDP trisodium) is a cytoprotective natural sugar phosphate for the potential treatment of sickle cell anemia, cardiovascular ischemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions.

Ferroportin-IN-1 is an inhibitor of the iron transport protein Ferroportin, which regulates cellular iron efflux and metabolism to study diseases caused by iron-modulating deficiencies or disorders of iron metabolism, used in metabolism studies such as thalassemia, sickle cell disease, and hemochromatosis.

dWIZ-1 ((rac)-dWIZ-1) is a potent WIZ molecular gel degrader that recruits WIZ (ZF7) to the cereblon thereby inducing degradation and thus induction of haemoglobin fetalis (HbF) in erythroblasts, which can be used to study sickle cell disease (SCD).

Varespladib (LY315920), a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.

Senicapoc (ICA-17043) is a potent inhibitor of the Gardos channel that ameliorates RBC dehydration in the SAD mouse. It blocks Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 ± 2 nM (CLT IC50 = 100 ± 12 nM) and inhibits RBC dehydration with an IC50 of 30 ± 20 nM. Senicapoc is used in the treatment of Sickle Cell Disease and Sickle Cell Anemia.

Enprofylline (Enprofilina), a bronchodilator, acts primarily as a competitive nonselective phosphodiesterase inhibitor. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of sickle cell disease, diabetic neuropathy, and cerebrovascular insufficiency.

ASP8731 is a selective inhibitor of BACH1 that prevents inflammation and vascular occlusion, and induces fetal hemoglobin in sickle cell disease.

MS8511 (hydrochloride) is a specific covalent and irreversible inhibitor of G9a GLP, targeting the cysteine residue at the substrate binding site. It has an IC50 of 100 nM for G9a and 140 nM for GLP, with Kd values of 44 nM for G9a and 46 nM for GLP. This compound reduces intracellular H3K9me2 levels and enhances antiproliferative activity, making it useful for studying various cancers, including brain, breast, ovarian, lung, bladder cancers, melanoma, and colorectal cancer, as well as other diseases like Alzheimer's disease (AD), sickle cell disease, and Prader-Willi syndrome (PWS).

WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.

RN-1 dihydrochloride is an effective and selective irreversible inhibitor of lysine-specific demethylase 1 (LSD1, IC50 = 70 nM).

Rivipansel is a glycomimetic compound. It acts as a pan-selectin antagonist and reverses acute vascular occlusions in sickle cell mice.

N-Phenylacetylphenylalanine is a biaromatic agent with properties that make them suitable candidates for the treatment of sickle cell disease.

L-Arginine-15N4 ((S)-(+)-Arginine-15N4) hydrochloride, the 15N-labeled variant of L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride), serves as the nitrogen donor in the synthesis of nitric oxide. This potent vasodilator is crucial, especially during a sickle cell crisis where its levels are notably diminished.

PRMT5-IN-14 is a PRMT5 inhibitor used to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

FTX-6058 is a potent orally active inhibitor targeting Embryonic Ectoderm Development (EED). It effectively induces HbF protein expression in both cell and murine models. This compound holds significant potential for researching select hemoglobinopathies such as sickle cell disease and β-thalassemia.

FTX-6058 hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED), with the ability to induce HbF protein expression in both cell and murine models. This compound is particularly valuable in the research of select hemoglobinopathies, such as sickle cell disease and β-thalassemia.

Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].

Pociredir (FTX-6058) is a potent, selective, and orally active inhibitor of embryonic ectoderm development (EED) with a KD of 0.163 nM, possessing research value in inflammatory conditions or hemoglobinopathies such as sickle cell disease (SCD).